الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 303 |  |  |
| | | from | 303 | | |
Abstract
Domperidone (DMP), is a dopamine (D2) receptor antagonist,
widely used for the treatment and prevention of acute nausea and
vomiting in adults from any cause especially those associated with
anticancer chemotherapy, radiotherapy and L-dopa and bromocriptine
treatment for parkinsonian patients. It is used also in stimulating gut
motility as a treatment of non-ulcer dyspepsia, esophageal reflux, gastritis
and functional dyspepsia.
DMP has a poor oral bioavailability ranging from 13-17% due to its
weakly-basic nature leading to low dissolution rate at relatively-high pH
values lowering its absorption and consequently, the bioavailability. Also,
DMP is subjected to extensive first-pass metabolism in gut wall and liver.
The aim of this work was to enhance the bioavailability of DMP
through dealing with the previously-mentioned problems related to its
dissolution and bioavailability. This was achieved through formulation of
new dosage forms of the drug.